As Amended by Senate Committee

Session of 2018

SENATE BILL No. 263

By Senator Kerschen

1-5

AN ACT concerning—agriculture {industrial hemp}; enacting the alternative crop research act; {excluding industrial hemp from definition of marijuana and cannabinoids;} amending K.S.A. 2017 Supp. {21-5701,} 21-5702{, 65-4101 and 65-4105} and repealing the existing-section {sections}.

Be it enacted by the Legislature of the State of Kansas:

New Section 1. (a) Sections 1 and 2, and amendments thereto, shall be known and may be cited as the alternative crop research act.

- (b) As used in the alternative crop research act:
- (1) "Certified seed" means industrial hemp seed that has been certified by a certifying agency, as defined by K.S.A. 2-1415, and amendments thereto, as having a delta-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry weight basis.
- (2) "Delta-9 tetrahydrocannabinol concentration" means the combined percentage of delta-9 tetrahydrocannabinol and its optical isomers, their salts and acids, and salts of their acids, reported as free THC on a dry weight basis, of any part of the plant cannabis sativa L.
 - (2) (3) "Department" means the Kansas department of agriculture.
- (3) (4) "Grower" means any person who has been approved and licensed by the department to grow or cultivate industrial hemp for the purposes of this act.
- (5) "Hemp products" means all products made from industrial hemp, including, but not limited to, cloth, cordage, fiber, food, fuel, paint, paper, particleboard, plastics, seed, seed-metal meal and seed oil for consumption and certified seed for cultivation, if the seeds originate from industrial hemp varieties.
- (4) (6){(5)} "Industrial hemp" means all parts and varieties of the plant cannabis sativa L., cultivated or possessed by a state educational institution, a grower or the department, whether growing or not, that contain a delta-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry weight basis.
- (5)(7) "Person" includes an individual, partnership, corporation,-association or other legal entity.

- (8){(6)} "Seed research" means research conducted to develop or recreate better strains of industrial hemp, particularly for the purpose of seed production.
- (6) (9){(7)} "State educational institution" means the university of Kansas, Kansas state university, Wichita state university, Emporia state university, Pittsburg state university and Fort Hays state university.
- (7) "Tetrahydrocannabinol" or "THC" means the natural or synthetic equivalents of the substances contained in the plant or in the resinous-extractives of cannabis or any synthetic substances, compounds, salts or derivatives of the plant or chemicals and their isomers with similar-ehemical structure and pharmacological activity.
- New Sec. 2. (a) The department, alone or in coordination with a state educational institution—*or any grower*, may cultivate industrial hemp grown from certified seed and promote the research and development of industrial hemp. This research may include:
- (1) Oversight and analysis of growth of industrial hemp to conduct agronomy research and analysis of required soils, growing conditions and harvest methods relating to the production of various varieties of industrial hemp that may be suitable for various commercial hemp products;
- (2) seed research on various types of industrial hemp that are best suited to be grown in Kansas, including seed availability, creation of hybrid types, in-the-ground variety trials and seed production;
- (3) analysis on the economic feasibility of developing an industrial hemp market in various types of industrial hemp that can be grown in Kansas;
- (4) analysis on the estimated value-added benefits, including environmental benefits, that Kansas businesses would reap by having an industrial hemp market of Kansas-grown industrial hemp varieties;
- (5) a study on the agronomy research conducted worldwide relating to industrial hemp varieties, production and utilization; and
- (6) a study on the feasibility of attracting federal and private funding for industrial hemp research; *and*
- (7) a pilot program in Russell county for the purpose of economic development and market research of industrial hemp and industrial hemp products.
- (b) The department shall oversee and annually license all—persons {individuals} participating in the cultivation, growth, research, oversight, study, analysis or transportation of certified seed or industrial hemp pursuant to this act.
- (c) (1) The department shall require, as a qualification for initial or continuing licensure, all—persons {individuals} seeking a license or license renewal under this act to be fingerprinted and to submit to a state and national criminal history record check. The fingerprints shall be

used to identify the—person {individual} and to determine whether the person {individual} has a record of criminal history in this state or any other jurisdiction. The department is authorized to submit the fingerprints to the Kansas bureau of investigation and the federal bureau of investigation for a state and national criminal history record check. The department may use the information obtained from fingerprinting and the criminal history record check for purposes of verifying the identification of the—person {individual} and for making an official determination of the qualifications for initial or continuing licensure pursuant to this act and rules and regulations promulgated pursuant to this act. Disclosure or use of any information received by the department for any purpose other than the purpose provided for in this section shall be a class A misdemeanor and shall constitute grounds for removal from office or termination of employment.

- (2)—A person {An individual} who has been convicted of any of the following shall be disqualified from initial or continuing licensure under this act: A felony violation of article 57 of chapter 21 of the Kansas Statutes Annotated, and amendments thereto, K.S.A. 2010 Supp. 21-36a01 through 21-36a17, prior to their transfer, or any felony violation of any provision of the uniform controlled substances act, prior to July 1, 2009.
- (3) The Kansas bureau of investigation may charge a reasonable fee for conducting a criminal history record check.
- (4) The applicant shall pay the costs of fingerprinting and the state and national criminal history record check.
- (b)(d) The secretary of agriculture shall—have the authority to-promulgate rules and regulations to carry out the provisions of the alternative crop research act on or before December 31, 2018. Such rules and regulations shall include, but not be limited to, a requirement that license holders shall have a current license in their possession at all times that they are engaged in cultivation, growth, research, oversight, study, analysis or transportation of certified seed or industrial hemp pursuant to this act.
- (e) The department shall submit a report to the legislature outlining the steps and timeline to implement a process that would allow-persons {individuals and business entities} to grow and process industrial hemp in Kansas and to sell industrial hemp in other states. Such report shall be submitted to the senate standing committee on agriculture and natural resources on or before January 14, 2019.
- (e)(f) Nothing in the alternative crop research act shall be construed to authorize any person {individual} to violate any state or federal law.
- 42 {Sec. 3. K.S.A. 2017 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2017 Supp. 21-5701 through 21-

- 5717, and amendments thereto: (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
- (b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
- (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
- (B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
 - (2) "Controlled substance analog" does not include:
 - (A) A controlled substance;
- (B) a substance for which there is an approved new drug application; or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
- (c) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.
- (d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.
 - (e) "Drug" means:
- (1) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them;

- (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or animals;
- (3) substances, other than food, intended to affect the structure or any function of the body of man or animals; and
- (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.
- (f) "Drug paraphernalia" means all equipment and materials of any kind which are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act. "Drug paraphernalia" shall include, but is not limited to:
- (1) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant which is a controlled substance or from which a controlled substance can be derived;
- (2) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;
- (3) isomerization devices used or intended for use in increasing the potency of any species of plant which is a controlled substance;
- (4) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;
- (5) scales and balances used or intended for use in weighing or measuring controlled substances;
- (6) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose, which are used or intended for use in cutting controlled substances;
- (7) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
- (8) blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
- (9) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
- (10) containers and other objects used or intended for use in storing or concealing controlled substances;
- (11) hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body;
- (12) objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine,

3

4

5

6 7

8

9 10

11

12

13 14

15

16

17

18

19

25

26

27

28

29

30

31

32

33 34

35

36

37

38

39

40

41 42

43

hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:

- (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls;
- (B) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
- (C) carburetion pipes, glass or other heat resistant tubes or any other device used, intended to be used or designed to be used to cause vaporization of a controlled substance for inhalation;
 - (D) smoking and carburetion masks;
- (E) roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand;
 - (F) miniature cocaine spoons and cocaine vials;
 - (G) chamber smoking pipes;
 - (H) carburetor smoking pipes;
 - (I) electric smoking pipes;
- (J) air-driven smoking pipes;
- 20 (K) chillums;
- 21 *(L) bongs*;
- 22 (M) ice pipes or chillers;
- 23 (N) any smoking pipe manufactured to disguise its intended 24 purpose;
 - (O) wired cigarette papers; or
 - (P) cocaine freebase kits.

"Drug paraphernalia" shall not include any products, chemicals or materials described in K.S.A. 2017 Supp. 21-5709(a), and amendments thereto.

- (g) "Immediate precursor" means a substance which the state board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
 - (h) "Isomer" means all enantiomers and diastereomers.
- (i) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:
 - (1) The preparation or compounding of a controlled substance by

 an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:

- (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or
- (2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose, which are intended for use in cutting a controlled substance.
- (j) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. "Marijuana" does not include: (1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant which is incapable of germination;—of (2) any substance listed in schedules II through V of the uniform controlled substances act; or (3) industrial hemp as defined in section 1, and amendments thereto.
 - (k) "Minor" means a person under 18 years of age.
- (l) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
 - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.
 - (m) "Opiate" means any substance having an addiction-forming or

 addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.

- (n) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (o) "Person" means [an] individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.
- (p) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (q) "Possession" means having joint or exclusive control over an item with knowledge of and intent to have such control or knowingly keeping some item in a place where the person has some measure of access and right of control.
- (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence imposed.
- (s) "Simulated controlled substance" means any product which identifies itself by a common name or slang term associated with a controlled substance and which indicates on its label or accompanying promotional material that the product simulates the effect of a controlled substance.
- Sec. 3. {4.} K.S.A. 2017 Supp. 21-5702 is hereby amended to read as follows: 21-5702. (a) Prosecutions for crimes committed prior to July 1, 2009, shall be governed by the law in effect at the time the crime was committed. For purposes of this section, a crime was committed prior to July 1, 2009, if any element of the crime occurred prior thereto.
- (b) The prohibitions of this act shall apply unless the conduct prohibited is authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act, *the alternative crop research act* or otherwise authorized by law.

- {Sec. 5. K.S.A. 2017 Supp. 65-4101 is hereby amended to read as follows: 65-4101. As used in this act: (a) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:
- (1) A practitioner or pursuant to the lawful direction of a practitioner; or
- (2) the patient or research subject at the direction and in the presence of the practitioner.
- (b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor or dispenser. It does not include a common carrier, public warehouseman or employee of the carrier or warehouseman.
- (c) "Application service provider" means an entity that sells electronic prescription or pharmacy prescription applications as a hosted service where the entity controls access to the application and maintains the software and records on its server.
 - (d) "Board" means the state board of pharmacy.
- (e) "Bureau" means the bureau of narcotics and dangerous drugs, United States department of justice, or its successor agency.
- (f) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
- (g) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
- (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
- (B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
 - (2) "Controlled substance analog" does not include:
 - (A) A controlled substance;

- (B) a substance for which there is an approved new drug application; or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
- (h) "Counterfeit substance" means a controlled substance which, or the container or labeling of which, without authorization bears the trademark, trade name or other identifying mark, imprint, number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance.
- (i) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.
- (j) "DEA" means the U.S. department of justice, drug enforcement administration.
- (k) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.
- (1) "Dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the packaging, labeling or compounding necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level practitioner.
- (m) "Dispenser" means a practitioner or pharmacist who dispenses, or a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto.
- (n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.
 - (o) "Distributor" means a person who distributes.
- (p) "Drug" means: (1) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them; (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human or animals; (3) substances (other than food) intended to affect the structure or any function of the body of human or animals; and (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.
- (q) "Immediate precursor" means a substance which the board has found to be and by rule and regulation designates as being the principal

 compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.

- (r) "Electronic prescription" means an electronically prepared prescription that is authorized and transmitted from the prescriber to the pharmacy by means of electronic transmission.
- (s) "Electronic prescription application" means software that is used to create electronic prescriptions and that is intended to be installed on the prescriber's computers and servers where access and records are controlled by the prescriber.
- (t) "Electronic signature" means a confidential personalized digital key, code, number or other method for secure electronic data transmissions which identifies a particular person as the source of the message, authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission.
- (u) "Electronic transmission" means the transmission of an electronic prescription, formatted as an electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer, where the data file is imported into the pharmacy prescription application.
- (v) "Electronically prepared prescription" means a prescription that is generated using an electronic prescription application.
- (w) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but is not limited to, transmission of a written prescription between the prescriber's fax machine and the pharmacy's fax machine; transmission of an electronically prepared prescription from the prescriber's electronic prescription application to the pharmacy's fax machine, computer or printer; or transmission of an electronically prepared prescription from the prescriber's fax machine to the pharmacy's fax machine, computer or printer.
- (x) "Intermediary" means any technology system that receives and transmits an electronic prescription between the prescriber and the pharmacy.
 - (y) "Isomer" means all enantiomers and diastereomers.
- (z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of

 its container, except that this term does not include the preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:

- (1) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance.
- (aa) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. It does not include: (1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant which is incapable of germination;—of (2) any substance listed in schedules II through V of the uniform controlled substances act; or (3) industrial hemp as defined in section 1, and amendments thereto.
- (bb) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425, and amendments thereto.
- (cc) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice of midwifery under the independent practice of midwifery act, an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs pursuant to a written protocol with a responsible physician under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto.
- (dd) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
 - (2) any salt, compound, isomer, derivative or preparation thereof

2 3

4

5

6 7

8

9 10

11

12 13

14 15

16

17

18

19

20

21

22

23

24

25

26

27 28

29

30 31

32

33

34

35

36

37

38

39

40

41

43

which is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;

- (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.
- "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory 3-methoxy-n-methylmorphinan (dextromethorphan). It does include its racemic and levorotatory forms.
- "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- "Person" means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership or association or any other legal entity.
- (hh) "Pharmacist" means any natural person licensed under K.S.A. 65-1625 et seg., and amendments thereto, to practice pharmacy.
- "Pharmacist intern" means: (1) A student currently enrolled in an accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving such person's internship; or (3) a graduate of a pharmacy program located outside of the United States which is not accredited and who had successfully passed equivalency examinations approved by the board.
- "Pharmacy prescription application" means software that is used to process prescription information, is installed on a pharmacy's computers and servers, and is controlled by the pharmacy.
- "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance.
 - "Prescriber" means a practitioner or a mid-level practitioner.
- "Production" includes the manufacture, planting, cultivation, growing or harvesting of a controlled substance. 42
 - "Readily retrievable" means that records kept by automatic (00)

data processing applications or other electronic or mechanized
recordkeeping systems can be separated out from all other records
within a reasonable time not to exceed 48 hours of a request from the
board or other authorized agent or that hard-copy records are kept on
which certain items are asterisked, redlined or in some other manner
visually identifiable apart from other items appearing on the records.
(pp) "Ultimate user" means a person who lawfully possesses a
controlled substance for such person's own use or for the use of a
member of such person's household or for administering to an anima
owned by such person or by a member of such person's household.
Sec. 6. K.S.A. 2017 Supp. 65-4105 is hereby amended to read as
follows: 65-4105. 65-4105. (a) The controlled substances listed in this
section are included in schedule I and the number set forth opposite
each drug or substance is the DEA controlled substances code which has
been assigned to it.
(b) Any of the following opiates, including their isomers, esters
ethers, salts, and salts of isomers, esters and ethers, unless specifically
excepted, whenever the existence of these isomers, esters, ethers and
salts is possible within the specific chemical designation:
(1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)
9821
(2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
piperidinyl]-N-phenylacetamide)9815
(3) Acetylmethadol9602
(4) AH-7921 (3,4-dichloro-N-[(1-
dimethylamino)cyclohexylmethyl]benzamide)955
(5) Allylprodine9602
(6) Alphacetylmethadol9603
(except levo-alphacetylmethadol also known as levo-alpha-
acetylmethadol, levomethadyl acetate or LAAM)
(7) Alphameprodine9604
(8) Alphamethadol9603
(9) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-
piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
propanilido) piperidine)9814
(10) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
piperidinyl]-N-phenylpropanamide)9832
(11) Benzethidine9600
(12) Betacetylmethadol9607
(13) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
piperidinylJ-N-phenylpropanamide)9830
(14) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-

phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)......9831

1	(15)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-	
2	, ,	yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)	9836
3	(16)	Betameprodine	
4	(17)	Betamethadol	9609
5	(18)	Betaprodine	9611
6	(19)	Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
7	` _	phenylbutyramide)	9822
8	(20)		
9	(21)	Dextromoramide	
10		Diampromide	
11	(23)	Diethylthiambutene	
12	(24)	Difenoxin	
13	(25)	Dimenoxadol	
14	(26)	Dimepheptanol	
15	(27)	Dimethylthiambutene	
16	(28)	Dioxaphetyl butyrate	
17	(29)	Dipipanone	
18	(30)	Ethylmethylthiambutene	
19	(31)		
20		Etoxeridine	
21		Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfu	
22	()	carboxamide)	
23	(34)		
24	(35)		
25	(36)	Ketobemidone	
26	(37)	Levomoramide	
27			
28	(39)		
29	()	phenylpropanamide)	
30	(40)		, 010
31	()	piperidinyl]-N-phenylpropanamide)	9833
32	(41)		
33	, ,	O-desmethyltramadol	
34	()	Some trade or other names: 2-((dimethylamino)methyl-1-(3-	
35		hydroxyphenyl)cyclohexanol;3-(2-((dimethylamino)methyl)-	1-
36		hydroxycyclohexyl)phenol	_
37	(43)		9661
38	(44)		
39	(45)	·	
40	(46)	Normethadone	
41	(47)		
42	(48)	* *	
43	(1.5)	niperidinyllpropanamide)	

1	(49)	PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine)	9663
2	(50)	Phenadoxone	9637
3	(51)	Phenampromide	9638
4	(52)	Phenomorphan	9647
5		Phenoperidine	
6		Piritramide	
7		Proheptazine	
8		Properidine	
9		Propiram	
10		Racemoramide	
11	<i>(59)</i>		
12	` ′	propanamide)	
13	(60)		
14	(61)		9646
15		U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-	V -
16	` /	methylbenzamide)	
17	(0	c) Any of the following opium derivatives, their salts, iso	mers and
18		of isomers, unless specifically excepted, whenever the ex	
19	these	e salts, isomers and salts of isomers is possible within th	e specific
20	chen	nical designation:	
21	(1)	Acetorphine	9319
22	<i>(2)</i>	Acetyldihydrocodeine	
23	(3)	Benzylmorphine	
24	(4)	Codeine methylbromide	
25	(5)	Codeine-N-Oxide	9053
26	(6)	Cyprenorphine	9054
27	(7)	Desomorphine	
28	(8)	Dihydromorphine	
29	(9)	Drotebanol	
30	(10)		
31	(11)	Heroin	
32	(12)		
33	(13)		
34	(14)	Methyldihydromorphine	9304
35	(15)	Morphine methylbromide	9305
36	(16)	Morphine methylsulfonate	9306
37	(17)		
38	(18)		
39	(19)	Nicocodeine	
40	(20)	Nicomorphine	9312
11		Normorphine	
12		Pholcodine	
13	, ,	Thehacon	9315

1		i) Any materiai, compouna, mixture or preparation wnich
2		ains any quantity of the following hallucinogenic substances, their
3		, isomers and salts of isomers, unless specifically excepted,
4		never the existence of these salts, isomers and salts of isomers is
5	poss	ible within the specific chemical designation:
6	(1)	Alpha-ethyltryptamine 7249 Some trade or other names:
7		etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-
8		aminobutyl) indole; α-ET; and AET.
9	(2)	4-bromo-2,5-dimethoxy-amphetamine7391
10		Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-
11		methylphenethylamine; 4-bromo-2,5-DMA.
12	(3)	2,5-dimethoxyamphetamine
13	, ,	Some trade or other names: 2,5-dimethoxy-alpha-methyl-
14		phenethylamine; 2,5-DMA.
15	(4)	4-methoxyamphetamine
16	, ,	Some trade or other names: 4-methoxy-alpha-methylphene-
17		thylamine; paramethoxyamphetamine; PMA.
18	(5)	5-methoxy-3,4-methylenedioxy-amphetamine7401
19	(6)	4-methyl-2,5-dimethoxy-amphetamine7395
20	• •	Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-
21		methylphenethylamine; "DOM"; and "STP".
22	(7)	3,4-methylenedioxy amphetamine7400
23	(8)	3,4-methylenedioxymethamphetamine (MDMA)7405
24	(9)	3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-
25	, ,	alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA,
26		MDE, and MDEA)
27	(10)	N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-
28	, ,	hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine, and
29		<i>N-hydroxy MDA</i>)
30	(11)	
31	(12)	Bufotenine
32	, ,	Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-
33		hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-
34		dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.
35	(13)	Diethyltryptamine
36	` ′	Some trade or other names: N,N-Diethyltryptamine; DET.
37	(14)	Dimethyltryptamine
38	` ′	Some trade or other names: DMT.
39	(15)	<i>Ibogaine</i>
10	` /	Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-
11		octahydro-2-methoxy-6,9-methano -5H-pyrido[1',2':1,2] azepino
12		[5,4-b]indole; Tabernanthe iboga
13	(16)	Lysergic acid diethylamide7315

1	(17)	<i>Marijuana7360</i>
2	(18)	<i>Mescaline7381</i>
3	<i>(19)</i>	Parahexyl
4	` ′	Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-
5		tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.
6	(20)	Peyote
7	` /	Meaning all parts of the plant presently classified botanically as
8		Lophophora williamsii Lemaire, whether growing or not, the seeds
9		thereof, any extract from any part of such plant, and every
10		compound, manufacture, salts, derivative, mixture or preparation
11		of such plant, its seeds or extracts.
12	(21)	N-ethyl-3-piperidyl benzilate7482
13		N-methyl-3-piperidyl benzilate7484
14		Psilocybin
15		Psilocyn
16	()	Some trade or other names: Psilocin.
17	(25)	Ethylamine analog of phencyclidine7455
18	` /	Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine;
19		(1-phenylcyclohexyl)ethylamine; N-(1-
20		phenylcyclohexyl)ethylamine; cyclohexamine; PCE.
21	(26)	Pyrrolidine analog of phencyclidine
22	` /	Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine;
23		PCPv: PHP
24	(27)	Thiophene analog of phencyclidine7470
25	` ′	Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-
26		piperidine; 2-thienyl analog of phencyclidine; TPCP; TCP.
27	(28)	1-[1-(2-thienyl)-cyclohexyl] pyrrolidine
28		Some other names: TCPy.
29	(29)	2,5-dimethoxy-4-ethylamphetamine7399
30	, ,	Some trade or other names: DOET.
31	(30)	Salvia divinorum or salvinorum A; all parts of the plant presently
32		classified botanically as salvia divinorum, whether growing or not,
33		the seeds thereof, any extract from any part of such plant, and
34		every compound, manufacture, salts, derivative, mixture or
35		preparation of such plant, its seeds or extracts.
36	(31)	Datura stramonium, commonly known as gypsum weed or jimson
37		weed; all parts of the plant presently classified botanically as
38		datura stramonium, whether growing or not, the seeds thereof, any
39		extract from any part of such plant, and every compound,
40		manufacture, salts, derivative, mixture or preparation of such
41		plant, its seeds or extracts.
42	(32)	N-benzylpiperazine7493
43		Some trade or other names: BZP.

1	(33)	1-(3-[trifluoromethylphenyl])piperazine
2		Some trade or other names: TFMPP.
3		4-Bromo-2,5-dimethoxyphenethylamine7392
4	(35)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical
5		isomers, salts and salts of optical isomers7348
6		Alpha-methyltryptamine (other name: AMT)7432
7	(37)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers,
8		salts and salts of isomers7439
9		2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)7509
10		2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7508
11		2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)7519
12		2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)
13		2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)7385
14	(43)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
15		7532
16		2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)7517
17		2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)7521
18		2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)7524
19	(47)	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)7431
20		Some trade or other names: 5-methoxy-3-[2-(dimethylamino)
21		ethyl]indole.
22	(48)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
23		ethanamine
24		Some trade or other names: 25I-NBOMe; 2C-I-NBOMe; 25I;
25		Cimbi-5.
26	(49)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
27		ethanamine7537
28		Some trade or other names: 25C-NBOMe; 2C-C-NBOMe; 25C;
29		Cimbi-82.
30	(50)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
31		methoxybenzyl)ethanamine
32		Some trade or other names: 25B-NBOMe; 2C-B-NBOMe; 25B;
33		Cimbi-36.
34	(51)	2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
35	(50)	Some trade or other names: 25H-NBOMe.
36	(52)	2-(2,5-dimethoxy-4-methylphenyl)-N-(2-
37		methoxybenzyl)ethanamine
38	/ - -\	Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.
39	(53)	2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl) ethanamine
40	,	Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.
41	,	e) Any material, compound, mixture or preparation which
42		ains any quantity of the following substances having a depressant
43	ettec	t on the central nervous system, including its salts, isomers, and

1	salts	of isomers whenever the existence of such salts, isomers, and salts
2		omers is possible within the specific chemical designation:
3	(1)	Etizolam
4		Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-
5		6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
6	(2)	Mecloqualone2572
7	(3)	Methaqualone2565
8	(4)	<u> •</u>
9	Ú	f) Unless specifically excepted or unless listed in another schedule,
10	any	material, compound, mixture or preparation which contains any
11	quai	ntity of the following substances having a stimulant effect on the
12		ral nervous system, including its salts, isomers and salts of isomers:
13	(1)	Aminorex 1585
14		Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline
15		or 4,5-dihydro-5-phenyl-2-oxazolamine
16	(2)	Fenethylline1503
17	(3)	N-ethylamphetamine1475
18	(4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-2-
19		oxazolamine)1590
20	(5)	N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-
21		benzeneethanamine; N,N-alpha-trimethylphenethylamine)1480
22	(6)	Cathinone (some other names: 2-amino-1-phenol-1-propanone,
23		alpha-amino propiophenone, 2-amino propiophenone and
24		norphedrone)1235
25	(7)	Substituted cathinones
26		Any compound, except bupropion or compounds listed under a
27		different schedule, structurally derived from 2-aminopropan-1-
28		one by substitution at the 1-position with either phenyl, naphthyl,
29		or thiophene ring systems, whether or not the compound is further
30		modified in any of the following ways:
31		(A) By substitution in the ring system to any extent with alkyl,
32		alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
33		substituents, whether or not further substituted in the ring
34		system by one or more other univalent substituents;
35		(B) by substitution at the 3-position with an acyclic alkyl
36		substituent;
37		(C) by substitution at the 2-amino nitrogen atom with alkyl,
38		dialkyl, benzyl, or methoxybenzyl groups; or
39		(D) by inclusion of the 2-amino nitrogen atom in a cyclic
40		structure.
41	0	g) Any material, compound, mixture or preparation which
42	cont	ains any quantity of the following substances:
13		N_[1_hanzvl_1_ninaridvll_N_nhanvlnronanamida (hanzvlfantanvl)

1		its optical isomers, salts and salts of isomers9818
2	(2)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
3	()	(thenylfentanyl), its optical isomers, salts and salts of isomers 9834
4	(h) Except industrial hemp as defined in section 1, and amendments
5		eto, any of the following cannabinoids, their salts, isomers and salts
6		somers, unless specifically excepted, whenever the existence of these
7		s, isomers and salts of isomers is possible within the specific
8		nical designation:
9	(1)	Tetrahydrocannabinols7370
0	(1)	Meaning tetrahydrocannabinols naturally contained in a plant of
1		the genus Cannabis (cannabis plant), as well as synthetic
2		equivalents of the substances contained in the plant, or in the
3		resinous extractives of Cannabis, sp. and/or synthetic substances,
4		derivatives, and their isomers with similar chemical structure and
5		pharmacological activity such as the following: Delta 1 cis or trans
6		tetrahydrocannabinol, and their optical isomers Delta 6 cis or trans
		tetrahydrocannabinol, and their optical isomers Delta 3,4 cis or
8		trans tetrahydrocannabinol, and its optical isomers (Since
9		nomenclature of these substances is not internationally
20		standardized, compounds of these structures, regardless of
21	(2)	numerical designation of atomic positions covered.)
22	(2)	Naphthoylindoles 2 (1 14 1): 11
23		Any compound containing a 3-(1-naphthoyl)indole structure with
4		substitution at the nitrogen atom of the indole ring by an alkyl,
25		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-
6		methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl group,
27		whether or not further substituted in the indole ring to any extent
8.		and whether or not substituted in the benzyl or naphthyl ring to
9		any extent.
0	(3)	Naphthylmethylindoles
1		Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane
2		structure with substitution at the nitrogen atom of the indole ring
3		by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
4		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
5		group whether or not further substituted in the indole ring to any
6		extent and whether or not substituted in the benzyl or naphthyl
7		ring to any extent.
8	(4)	Naphthoylpyrroles
9		Any compound containing a 3-(1-naphthoyl)pyrrole structure with
0		substitution at the nitrogen atom of the pyrrole ring by an alkyl,
-1		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-
2		methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group
3		whather or not further substituted in the nurrale ring to any extent

whether or not substituted in the benzyl or naphthyl ring to any extent.
(5) Naphthylmethylindenes
Any compound containing a naphthylideneindene structure with

Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the benzyl or naphthyl ring to any extent.

(6) Phenylacetylindoles

5

6 7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the benzyl or phenyl ring to any extent.

(7) Cyclohexylphenols

Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent.

(8) Benzoylindoles

Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the benzyl or phenyl ring to any extent.

33 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 34 1,4-benzoxazin-6-yl]-1-napthalenylmethanone.
35 Some trade or other names: WIN 55,212-2.

(10) 9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-210, HU-211.

39 (11) Tetramethylcyclopropanoylindoles

40 Any compound containing a 3-tetramethylcyclopropanoylindole 41 structure with substitution at the nitrogen atom of the indole ring 42 by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 43 cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-

40

publication in the statute book.

1 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-2 methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, 3 whether or not further substituted in the indole ring to any extent 4 and whether or not substituted in the benzyl or 5 tetramethylcyclopropyl rings to any extent. 6 (12) Indole-3-carboxylate esters 7 Any compound containing a 1H-indole-3-carboxylate ester 8 structure with the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or adamantyl group and substitution at the 1 position 9 of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 10 cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl or 2-(4-11 12 morpholinyl)ethyl group, whether or not further substituted on the 13 indole ring to any extent and whether or not substituted on the 14 naphthyl, quinolinyl, isoquinolinyl, adamantyl or benzyl groups to 15 any extent. (13) Indazole-3-carboxamides 16 17 Any compound containing a 1H-indazole-3-carboxamide structure 18 with substitution at the nitrogen of the carboxamide by a naphthyl, 19 quinolinyl, isoquinolinyl, adamantyl, 1-amino-1-oxoalkan-2-yl or 20 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1 position 21 of the indazole ring by an alkyl, haloalkyl, alkenyl, 22 cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-23 piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not 24 further substituted on the indazole ring to any extent and whether 25 or not substituted on the naphthyl, quinolinyl, isoquinolinyl, 26 adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or 27 benzyl groups to any extent. 28 (14) (1H-indazol-3-yl)methanones 29 Any compound containing a (1H-indazol-3-yl)methanone structure 30 with the carbonyl carbon bearing a naphthyl group and 31 substitution at the 1 position of the indazole ring by an alkyl, 32 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-33 methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, 34 whether or not further substituted on the indazole ring to any 35 extent and whether or not substituted on the naphthyl or benzyl 36 groups to any extent.} 37 Sec.-4. {7.} K.S.A. 2017 Supp. {21-5701,} 21-5702-is{, 65-4101 and 38 65-4105 are} hereby repealed.

Sec. 5. [8.] This act shall take effect and be in force from and after its